Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | KDM2B | Q8NHM5 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GBA1 | P04062 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | SLC18A2 | Q05940 | 3/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9928853 | 0.86 | MEN1 (0.37) | MEN1ALDH1A1KMT2APOLBSLC18A2 | |
| SCHEMBL9928854 | 0.86 | MEN1 (0.37) | MEN1ALDH1A1KMT2APOLBSLC18A2 | |
| SCHEMBL3025369 | 0.80 | CYP46A1 (0.34) | ALDH1A1POLBGBA1 | |
| SCHEMBL3025364 | 0.80 | CYP46A1 (0.34) | ALDH1A1POLBGBA1 | |
| SCHEMBL1314601 | 0.80 | CYP46A1 (0.34) | ALDH1A1POLBGBA1 | |
| SCHEMBL2996591 | 0.80 | HPGD (0.44) | MEN1ALDH1A1KMT2A | |
| SCHEMBL3031676 | 0.79 | GABRR1 (0.35) | DPP4 | |
| SCHEMBL3033285 | 0.79 | GABRR1 (0.35) | DPP4 | |
| SCHEMBL3276769 | 0.79 | GABRR1 (0.35) | DPP4 | |
| SCHEMBL3033289 | 0.79 | GABRR1 (0.35) | DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100184805-A1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184805-A1 | RENIN INHIBITORS | ACE, REN, ACE2 | MEN1 3705/4885ALDH1A1 1238/4885KMT2A 4279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.